Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS – CoV ‐2 Messenger RNA Vaccination

4 Aug 2021

Abstract excerpt

OBJECTIVE: To evaluate disease flare and postvaccination reactions (reactogenicity) in patients with rheumatic and musculoskeletal diseases (RMDs) following 2-dose SARS-CoV-2 messenger RNA (mRNA) vaccination. METHODS: RMD patients (n = 1,377) who received 2-dose SARS-CoV-2 mRNA vaccination between December 16, 2020 and April 15, 2021 completed questionnaires detailing local and systemic reactions experienced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Rheumatoid Arthritis Research and Therapies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34346185
DOI: 10.1002/art.41924

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS – CoV ‐2 Messenger RNA VaccinationPMID 34346185Read ↗

Anti-SARS-CoV-2 immunogenicity decay and incident cases six months after Sinovac-CoronaVac inactivated vaccine in autoimmune rheumatic diseases patients: phase 4 prospective trialSemantic proximity Read ↗

Clinical and immunological data from chronic urticaria onset after mRNA SARS‐CoV‐2 vaccinesSemantic proximity Read ↗

Safety of Coronavac and ChAdOx1 Vaccines Against SARS-CoV-2 in Patients with Rheumatoid Arthritis Data from the Brazilian Multicentric Study SaferSemantic proximity Read ↗

Safety and Efficacy of Inactivated Sars-Cov-2 Vaccine in Patients with Rheumatic Diseases and Serum Antibody Changes Post-Omicron Variant InfectionSemantic proximity Read ↗

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal diseaseSemantic proximity Read ↗

Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: a systematic review and meta-analysisSemantic proximity Read ↗

Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patientsSemantic proximity Read ↗

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from GreeceSemantic proximity Read ↗

Post-Vaccination Symptoms after A Third Dose of mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel DiseaseSemantic proximity Read ↗

Cardiac Inflammation after COVID-19 mRNA Vaccines: A Global Pharmacovigilance AnalysisSemantic proximity Read ↗

Self-Reported Adverse Events Following SARS-CoV-2 Vaccination: A Nationwide Questionnaire Study in the Adult Danish PopulationSemantic proximity Read ↗

Immunogenicity and safety of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.